Clinical and Experimental Pediatrics

Search

Search

Close


Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-11.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 93

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 94

All issues > Volume 41(2); 1998

Original Article
J Korean Pediatr Soc. 1998;41(2):216-223. Published online February 15, 1998.
High Dose of Amphotericin B in Intralipid Emulsion-based Delivery System in Immunocompromised Children with Invasive Fungal Infections
Geun Mo GM Kim1, Hoon H Kook1, Sung Ho SH Cho1, Ji Yong JY Park1, Young Jong YJ Woo1, Tai Ju TJ Hwang1
1Department of Pediatrics, College of Medicine, Chonnam University, Kwangju, Korea
Correspondence Geun Mo GM Kim ,Email: 1
Abstract
Purpose
: Fungal infections are an important cause of morbidity and mortality in patients with hematologic malignancies. The therapy of choice in documented or suspected invasive fungal infections has been intravenous Amphotericin B(AmB). Adverse effects such as fever, chills, thrombophlebitis, nausea or vomiting are common. A more serious adverse effect is potential renal impairment. As AmB administration mixed with Intralipid(AmB/Intralipid) was reported to decrease AmB toxicity without a concomitant loss of antifungal efficacy, we studied the efficacy and side effects of long-term administration of AmB/Intralipid in leukemic children with invasive fungal diseases.
Methods
: AmB/Intralipid was administered in seven leukemic children(male, 3; female, 4) who had invasive fungal infections between July 1994 and March 1997.
Results
: AmB/Intralipid was administered at a mean concentration of 1.45mg/kg/day for a mean of 58.1 days with cumulative dose of 3.01g. Excluding 2 patients who succumbed to the underlying leukemia, 4 out of 5 remaining patients remained free of both fungal infection and leukemia. Chills associated with AmB/Intralipid were found 13 times in 4 patients. One patient could not continue the administration because of the chills on the 45th day of AmB/Intralipid. Renal and hepatic impairment greater than Grade II toxicity was found in each case, respectively. The other 6 patients showed mild elevation from the baseline, but remained within the normal limits.
Conclusion
: Long-term, high-dose AmB/Intralipid therapy can be safely and effectively used in immunocompromised children with invasive fungal infections.

Keywords :High dose amphotericin B, Renal toxicity, Intralipid amphotericin B, Invasive fungal infection

Go to Top